ArticleJournal of cardiovascular translational research2026
Metabolite-based Analysis of High-Risk Factors on Occurrence of AKI in Patients with Acute Myocardial Infarction.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current methods lack high‑risk identification for acute kidney injury (AKI) after acute myocardial infarction (AMI). This study aimed to develop a metabolic‑biomarker‑based predictive system. 124 AMI patients (July 2023-October 2024) were enrolled prospectively. Logistic regression, ROC curves, and Pearson correlation were used to assess predictive values. Post-PCI kidney injury incidence was 19.39% (n = 19). The injury group showed higher LVEF, FFA, and Killip ≥ 2 rates (P < 0.05), but lower 5-MTP and UMOD (P < 0.05). FFA, 5-MTP, and UMOD were independent risk factors (P < 0.05), with combined AUC = 0.931 (superior to single markers, P < 0.05). BUN, UA, SCr, and eGFR correlated strongly with these metabolites (P < 0.05). LVEF, 5‑MTP, and UMOD are key metabolic indicators for early AKI risk identification. The integrated "biomarker+nursing" pathway improves early warning and outcomes in AMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.